GOREISAN for Heart Failure (GOREISAN-HF) Trial

Korábbi kezelés

• Valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization
• Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to enrollment or intent to implant a CRT device
• Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization
• Treatment with herbal medicine at enrollment

Más betegség

• Acute coronary syndrome at screening
• Confirmed poor tolerability of Goreisan (including cinnamon allergy)

Laborértékek

• End-stage renal failure (estimated glomerular filtration rate [eGFR] <15 mL/min/1.73m2) at enrollment

Egyéb

• Patients who are expected to have a life expectancy of 6 months or less
• Women of child-bearing potential or women who have a positive pregnancy test at enrolment or randomization
• Considered not appropriate for the participation of the study

• Confirmed congestive heart failure (CHF) by Framingham criteria
• CHF patients with cardiac edema and signs due to cardiac edema (signs of fluid overload: lower limb edema, pulmonary effusion, or pulmonary congestion on chest x-ray)
• Elevated N-terminal pro brain-type natriuretic peptide (NT-proBNP) ≥300 pg/mL or brain natriuretic peptide (BNP) ≥100 pg/mL at enrollment
• Patients ≥ 20 years of age, male or female
• Provision of signed informed consent before any assessment is performed